OTCMKTS:CMPD CompuMed (CMPD) Stock Price, News & Analysis $4.50 +0.50 (+12.50%) As of 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsShort InterestBuy This Stock About CompuMed Stock (OTCMKTS:CMPD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CompuMed alerts:Sign Up Key Stats Today's Range$4.50▼$4.5050-Day Range$3.30▼$4.7452-Week Range$2.40▼$6.80Volume100 shsAverage Volume2,881 shsMarket Capitalization$5.99 millionP/E Ratio26.47Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California. Read More CompuMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreCMPD MarketRank™: CompuMed scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CompuMed. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CompuMed is 26.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.52.Price to Earnings Ratio vs. SectorThe P/E ratio of CompuMed is 26.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.78.Price to Book Value per Share RatioCompuMed has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the outstanding shares of CompuMed have been sold short.Short Interest Ratio / Days to CoverCompuMed has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CompuMed has recently decreased by 7.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompuMed does not currently pay a dividend.Dividend GrowthCompuMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.38% of the outstanding shares of CompuMed have been sold short.Short Interest Ratio / Days to CoverCompuMed has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CompuMed has recently decreased by 7.27%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for CMPD on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CompuMed insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of CompuMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CompuMed's insider trading history. Receive CMPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CompuMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPD Stock News HeadlinesCMPD arrests juvenile for handgun, marijuana possessionMay 6, 2025 | yahoo.comCompuMed, Inc. (CMPD) Latest Stock News & Headlines - Yahoo FinanceMay 4, 2025 | finance.yahoo.comWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock.September 10 at 2:00 AM | Chaikin Analytics (Ad)CMPD investigating after deadly shooting in Uptown CharlotteNovember 6, 2024 | yahoo.comCMPD to discuss theft ring caseAugust 24, 2024 | yahoo.comCompumed Inc.May 23, 2024 | wsj.comCompuMed, Inc.: CompuMed, FireStarter Collaborate to Further Shared Vision of Saving More Lives through Organ Donation and TransplantationMay 1, 2024 | finanznachrichten.deCompuMed, Inc. (CMPD) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | finance.yahoo.comSee More Headlines CMPD Stock Analysis - Frequently Asked Questions How have CMPD shares performed this year? CompuMed's stock was trading at $3.81 at the beginning of the year. Since then, CMPD stock has increased by 18.1% and is now trading at $4.50. How were CompuMed's earnings last quarter? CompuMed Inc. (OTCMKTS:CMPD) announced its quarterly earnings results on Monday, December, 16th. The company reported $0.02 EPS for the quarter. CompuMed had a net margin of 2.26% and a trailing twelve-month return on equity of 4.82%. When did CompuMed's stock split? CompuMed shares reverse split on Saturday, May 21st 2022.The 1-25 reverse split was announced on Saturday, May 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Saturday, May 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of CompuMed? Shares of CMPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CompuMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CompuMed investors own include Yamana Gold (AUY) and Agnico Eagle Mines (AEM). Company Calendar Last Earnings12/16/2024Today9/10/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED PRODUCTS Sub-IndustryBusiness Services Current SymbolOTCMKTS:CMPD CIKN/A Webwww.compumed.net Phone(310) 258-5000Fax310-645-5880Employees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.17 Trailing P/E Ratio26.47 Forward P/E RatioN/A P/E GrowthN/ANet Income$30 thousand Net Margins2.26% Pretax Margin0.17% Return on Equity4.82% Return on Assets3.32% Debt Debt-to-Equity Ratio0.16 Current Ratio2.28 Quick Ratio2.26 Sales & Book Value Annual Sales$6.22 million Price / Sales0.96 Cash Flow$0.77 per share Price / Cash Flow5.81 Book Value$2.49 per share Price / Book1.81Miscellaneous Outstanding Shares1,330,000Free Float1,034,000Market Cap$5.99 million OptionableNot Optionable Beta-0.05 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:CMPD) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CompuMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CompuMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.